医学
帕博西利布
不利影响
中性粒细胞减少症
细胞周期蛋白依赖激酶
肿瘤科
细胞周期蛋白依赖激酶4
转移性乳腺癌
药理学
内科学
乳腺癌
癌症
化疗
细胞周期
细胞周期蛋白依赖激酶2
出处
期刊:Breast Care
[Karger Publishers]
日期:2019-01-01
卷期号:14 (2): 86-92
被引量:46
摘要
Cyclin-dependent kinase (CDK) 4/6 inhibitors have become standard of care in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. They have been shown to double the efficacy of endocrine-based treatment. Three oral agents are available to date: palbociclib, ribociclib, and abemaciclib. The aim of this article is to give a short overview of the existing efficacy data, to summarize the recommended clinical monitoring procedures for patients under CDK4/6 inhibitors, and to shed light on the clinical management of the most common treatment-emergent adverse events. The hematological class side effect neutropenia as well as non-hematological toxicities (e.g., impaired liver function, prolonged QTc interval, and diarrhea) are discussed. In addition, the current knowledge about relevant drug interactions is reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI